|
1
|
Bol KF, Donia M, Heegaard S, Kiilgaard JF
and Svane IM: Genetic biomarkers in melanoma of the ocular region:
What the medical oncologist should know. Int J Mol Sci.
21:52312020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Singh AD, Turell ME and Topham AK: Uveal
melanoma: Trends in incidence, treatment, and survival.
Ophthalmology. 118:1881–1885. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kujala E, Mäkitie T and Kivelä T: Very
long-term prognosis of patients with malignant uveal melanoma.
Invest Ophthalmol Vis Sci. 44:4651–4659. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jensen OA: Malignant melanomas of the
human uvea: 25-year follow-up of cases in Denmark, 1943--1952. Acta
Ophthalmol (Copenh). 60:161–182. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Varssano D, Friedman M, Goldstein M,
Bar-Sela S, Sella T, Shalev V and Chodick G: Association between
cataract and keratinocytic skin cancers or melanoma: Speculating on
the common role of sun and ultraviolet radiation exposures.
Ophthalmic Epidemiol. 24:336–340. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fish GE, Jost BF, Snyder WI, Fuller DG and
Birch DG: Cataract extraction after brachytherapy for malignant
melanoma of the choroid. Ophthalmology. 98:619–622. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Factors predictive of growth and treatment
of small choroidal melanoma, . COMS Report No. 5. The Collaborative
Ocular Melanoma Study Group. Arch Ophthalmol. 115:1537–1544.
1997.PubMed/NCBI
|
|
8
|
Shields CL, Furuta M, Thangappan A, Nagori
S, Mashayekhi A, Lally DR, Kelly CC, Rudich DS, Nagori AV, Wakade
OA, et al: Metastasis of uveal melanoma millimeter-by-millimeter in
8033 consecutive eyes. Arch Ophthalmol. 127:989–998. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Manchegowda P, Singh AD, Shields C, Kaliki
S, Shah P, Gopal L and Rishi P: Uveal melanoma in Asians: A review.
Ocul Oncol Pathol. 7:159–167. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
McLaughlin CC, Wu XC, Jemal A, Martin HJ,
Roche LM and Chen VW: Incidence of noncutaneous melanomas in the
U.S. Cancer. 103:1000–1007. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Weinreb RN, Aung T and Medeiros FA: The
pathophysiology and treatment of glaucoma: A review. JAMA.
311:1901–1911. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Adam G, Brab M, Bohndorf K and Günther RW:
Gadolinium-DTPA-enhanced MRI of intraocular tumors. Magn Reson
Imaging. 8:683–689. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gomori JM, Grossman RI, Shields JA,
Augsburger JJ, Joseph PM and DeSimeone D: Choroidal melanomas:
Correlation of NMR spectroscopy and MR imaging. Radiology.
158:443–445. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Peyster RG, Augsburger JJ, Shields JA,
Hershey BL, Eagle R Jr and Haskin ME: Intraocular tumors:
Evaluation with MR imaging. Radiology. 168:773–779. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Design and methods of a clinical trial for
a rare condition, . The collaborative ocular melanoma study. COMS
report no. 3. Control Clin Trials. 14:362–391. 1993.PubMed/NCBI
|
|
16
|
Liu YM, Li Y, Wei WB, Xu X and Jonas JB:
Clinical characteristics of 582 patients with uveal melanoma in
China. PLoS One. 10:e01445622015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Diener-West M, Hawkins BS, Markowitz JA
and Schachat AP: A review of mortality from choroidal melanoma. II.
A meta-analysis of 5-year mortality rates following enucleation,
1966 through 1988. Arch Ophthalmol. 110:245–250. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
McLean IW, Foster WD, Zimmerman LE and
Gamel JW: Modifications of callender's classification of uveal
melanoma at the armed forces institute of pathology. Am J
Ophthalmol. 96:502–550. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kashyap S, Venkatesh P, Sen S, Khanduja S,
Shrey D, Tinwala S and Garg S: Clinicopathologic characteristics of
choroidal melanoma in a north Indian population: Analysis of
10-year data. Int Ophthalmol. 34:235–239. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Meeralakshmi P, Shah PK and Narendran V:
Experiences of two different modalities in the management of
choroidal melanoma in the Asian Indian population. South Asian J
Cancer. 6:134–136. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Diener-West M, Reynolds SM, Agugliaro DJ,
Caldwell R, Cumming K, Earle JD, Hawkins BS, Hayman JA, Jaiyesimi
I, Jampol LM, et al: Development of metastatic disease after
enrollment in the COMS trials for treatment of choroidal melanoma:
Collaborative ocular melanoma study group report no. 26. Arch
Ophthalmol. 123:1639–1643. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Steckler AM, Francis JH, Shoushtari AN,
Abramson DH and Barker CA: Uveal melanoma metastatic at initial
diagnosis: A case series. Melanoma Res. 32:120–123. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou N, Zhang R, Liu Y and Wei W: Clinical
characteristics of UM and association of metastasis of uveal
melanoma with congenital oculocutaneous melanosis in Asian
patients: Analysis of 1151 consecutive eyes. Ophthalmol Retina.
5:1164–1172. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jacobsen BH, Ricks C and Harrie RP: Ocular
ultrasound versus MRI in the detection of extrascleral extension in
a patient with choroidal melanoma. BMC Ophthalmol. 18:3202018.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Neupane R, Gaudana R and Boddu SHS:
Imaging techniques in the diagnosis and management of ocular
tumors: Prospects and challenges. AAPS J. 20:972018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kase S, Parikh JG, Youssef PN, Murphree AL
and Rao NA: Transforming growth factor beta in
retinoblastoma-related cataract. Arch Ophthalmol. 126:1539–1542.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Camp DA, Yadav P, Dalvin LA and Shields
CL: Glaucoma secondary to intraocular tumors: Mechanisms and
management. Curr Opin Ophthalmol. 30:71–81. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Onken MD, Worley LA, Ehlers JP and Harbour
JW: Gene expression profiling in uveal melanoma reveals two
molecular classes and predicts metastatic death. Cancer Res.
64:7205–7209. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Field MG, Durante MA, Anbunathan H, Cai
LZ, Decatur CL, Bowcock AM, Kurtenbach S and Harbour JW: Punctuated
evolution of canonical genomic aberrations in uveal melanoma. Nat
Commun. 9:1162018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Harbour JW, Onken MD, Roberson ED, Duan S,
Cao L, Worley LA, Council ML, Matatall KA, Helms C and Bowcock AM:
Frequent mutation of BAP1 in metastasizing uveal melanomas.
Science. 330:1410–1413. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Karlsson J, Nilsson LM, Mitra S, Alsen S,
Shelke GV, Sah VR, Forsberg EMV, Stierner U, All-Eriksson C,
Einarsdottir B, et al: Molecular profiling of driver events in
metastatic uveal melanoma. Nat Commun. 11:18942020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Figueiredo CR, Kalirai H, Sacco JJ,
Azevedo RA, Duckworth A, Slupsky JR, Coulson JM and Coupland SE:
Loss of BAP1 expression is associated with an immunosuppressive
microenvironment in uveal melanoma, with implications for
immunotherapy development. J Pathol. 250:420–439. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xue Y, Meehan B, Fu Z, Wang XQD, Fiset PO,
Rieker R, Levins C, Kong T, Zhu X, Morin G, et al: SMARCA4 loss is
synthetic lethal with CDK4/6 inhibition in non-small cell lung
cancer. Nat Commun. 10:5572019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Guerrero-Martínez JA and Reyes JC: High
expression of SMARCA4 or SMARCA2 is frequently associated with an
opposite prognosis in cancer. Sci Rep. 8:20432018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ryu B, Kim DS, Deluca AM and Alani RM:
Comprehensive expression profiling of tumor cell lines identifies
molecular signatures of melanoma progression. PLoS One. 2:e5942007.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Latham A, Srinivasan P, Kemel Y, Shia J,
Bandlamudi C, Mandelker D, Middha S, Hechtman J, Zehir A,
Dubard-Gault M, et al: Microsatellite instability is associated
with the presence of lynch syndrome pan-cancer. J Clin Oncol.
37:286–295. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Balasubramanya R, Selvarajan SK, Cox M,
Joshi G, Deshmukh S, Mitchell DG and O'Kane P: Imaging of ocular
melanoma metastasis. Br J Radiol. 89:201600922016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Davidorf FH, Pajka JT, Makley TA Jr and
Kartha MK: Radiotherapy for choroidal melanoma. An 18-year
experience with radon. Arch Ophthalmol. 105:352–355. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lommatzsch PK: Results after
beta-irradiation (106Ru/106Rh) of choroidal melanomas. Twenty
years' experience. Am J Clin Oncol. 10:146–151. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gass JD: Comparison of prognosis after
enucleation vs cobalt 60 irradiation of melanomas. Arch Ophthalmol.
103:916–923. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Augsburger JJ, Gamel JW, Sardi VF,
Greenberg RA, Shields JA and Brady LW: Enucleation vs cobalt plaque
radiotherapy for malignant melanomas of the choroid and ciliary
body. Arch Ophthalmol. 104:655–661. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Augsburger JJ, Gamel JW, Lauritzen K and
Brady LW: Cobalt-60 plaque radiotherapy vs enucleation for
posterior uveal melanoma. Am J Ophthalmol. 109:585–592. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Rossi E, Schinzari G, Zizzari IG, Maiorano
BA, Pagliara MM, Sammarco MG, Fiorentino V, Petrone G, Cassano A,
Rindi G, et al: Immunological backbone of uveal melanoma: Is there
a rationale for immunotherapy? Cancers (Basel). 11:10552019.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Javed A, Arguello D, Johnston C, Gatalica
Z, Terai M, Weight RM, Orloff M, Mastrangelo MJ and Sato T: PD-L1
expression in tumor metastasis is different between uveal melanoma
and cutaneous melanoma. Immunotherapy. 9:1323–1330. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
de Vries TJ, Trancikova D, Ruiter DJ and
van Muijen GN: High expression of immunotherapy candidate proteins
gp100, MART-I, tyrosinase and TRP-I in uveal melanoma. Br J Cancer.
78:1156–1161. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
de Vries TJ, Fourkour A, Wobbes T,
Verkroost G, Ruiter DJ and van Muijen GN: Heterogeneous expression
of immunotherapy candidate proteins gp100, MART-1, and tyrosinase
in human melanoma cell lines and in human melanocytic lesions.
Cancer Res. 57:3223–3229. 1997.PubMed/NCBI
|
|
47
|
Luyten GP, van der Spek CW, Brand I,
Sintnicolaas K, de Waard-Siebinga I, Jager MJ, de Jong PT, Schrier
PI and Luider TM: Expression of MAGE, gp100 and tyrosinase genes in
uveal melanoma cell lines. Melanoma Res. 8:11–16. 1998. View Article : Google Scholar : PubMed/NCBI
|
